Management of Carfilzomib-Associated Cardiac Adverse Events

Joseph R Mikhael

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2016

    Fingerprint

Keywords

  • Cardiopulmonary
  • Clinical trials
  • Multiple myeloma
  • Proteasome inhibitor
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this